Investing.com - Financial Markets Worldwide
Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Roche team develops armed antibody in antibiotic fight

Published 2015-11-04, 01:00 p/m
© Reuters. Roche team develops armed antibody in antibiotic fight
ROG
-

LONDON, Nov 4 (Reuters) - Researchers at Roche ROG.VX have
developed a new weapon to fight hard-to-treat bacteria by arming
an antibody with an antibiotic to reach and kill bugs hidden
inside cells.
The approach is similar to an existing technique used by
scientists at the Swiss group's biotech unit Genentech, which
arms antibodies with a chemotherapy drug to tackle cancer. That
system led to the development of the breast cancer drug Kadcyla.
In a paper in the journal Nature, the Genentech team
reported their new antibody-antibiotic conjugate (AAC) killed
Staphylococcus aureus in mice that standard potent antibiotics
failed to destroy.
Drug-resistant strains of S. aureus, or MRSA, are an
increasing concern in hospitals, where they can be deadly to
vulnerable patients.
The new AAC is designed to be inactive until it enters a
cell, when enzyme activity releases the antibiotic.
In an accompanying Nature commentary, Wolf-Dietrich Hardt at
Zurich's Institute of Microbiology said it remains to be seen
whether the AACs would be as good at treating bacterial
infections in humans as in mice.
But the approach is seen as promising, since it should cut
the emergence of antibiotic resistance by reducing exposure of
other bacteria to active drug, while also limiting damage to the
body's beneficial microbes.
In addition, it may allow scientists to look again at past
antibiotic drug candidates that were deemed too toxic to use but
which might be tolerated if loaded onto a highly targeted
antibody "missile".
Swiss drugmaker Roche, which last launched an antibiotic in
1982, has recently stepped up investment in the field, amid
growing public concern about the emergence of drug-resistant
superbugs.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.